Compared to IDH1/2-mutant astrocytomas and oligodendrogliomas, GBM exhibits significantly higher pathway co-activation, with the p53 pathway and cell cycle dysregulation being the most predominant ones. The gene discussed is TP53; the disease is astrocytoma (excluding glioblastoma).